Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development. The company’s platform is the first systematic, computationally-driven solution to achieve the molecular modelling accuracy necessary for rapid and cost-effective drug discovery.
Verseon plans to use its platform to establish a diversified discovery pipeline across multiple disease areas. Current drug programs include anticoagulation, diabetic macular edema, and oncology (solid tumors).